Duobrii vs. Tremfya

• Are Duobrii and Tremfya the Same Thing?
• What Are Possible Side Effects of Duobrii?
• What Are Possible Side Effects of Tremfya?
• What Is Duobrii?
• What Is Tremfya?
• What Drugs Interact with Duobrii?
• What Drugs Interact with Tremfya?
• How Should Duobrii Be Taken?
• How Should Tremfya Be Taken?

Duobrii (halobetasol propionate and tazarotene) and Tremfya (guselkumab) are used to treat plaque psoriasis in adults.

Duobrii Lotion is a topical (for the skin) treatment and Tremfya is given as a subcutaneous injection.

Duobrii and Tremfya belong to different drug classes. Duobrii is a combination of a corticosteroid and a retinoid and Tremfya is an interleukin-23 blocker.

Side effects of Duobrii that are different from Tremfya include contact dermatitis, application site pain, infected hair follicles, thinning skin, skin abrasions, rash, stretch marks, and skin peeling.

Side effects of Tremfya that are different from Duobrii include upper respiratory infections, headache, injection site reactions, joint pain, diarrhea, gastroenteritis (nausea, vomiting, diarrhea, cramps, and fever), tinea infections (athlete's foot, ringworm, jock itch), and herpes simplex infections.

Duobrii may interact with corticosteroids taken by mouth or injection and other products used on your skin that contain corticosteroids.

Tremfya may interact with “live” vaccines and CYP450 substrates.

Common side effects of Duobrii include:

• contact dermatitis,
• application site pain,
• infected hair follicles,
• thinning skin,
• skin abrasions,
• rash,
• stretch marks, and
• skin peeling

Common side effects of Tremfya include:

• upper respiratory infections,
• headache,
• injection site reactions,
• joint pain,
• diarrhea,
• gastroenteritis (nausea, vomiting, diarrhea, cramps, and fever),
• tinea infections (athlete's foot, ringworm, jock itch), and
• herpes simplex infections

Duobrii (halobetasol propionate and tazarotene) Lotion is a combination of a corticosteroid and a retinoid indicated for the topical treatment of plaque psoriasis in adults.

Tremfya (guselkumab) injection, for subcutaneous use is an interleukin-23 blocker indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Duobrii Lotion may interact with corticosteroids taken by mouth or injection, or other products used on your skin that contain corticosteroids. Tell your doctor all medications and supplements you use. Duobrii Lotion is not recommended for use during pregnancy; it may harm a fetus. A negative result for pregnancy should be obtained within 2 weeks prior to Duobrii Lotion therapy, which should begin during menstruation. Females of reproductive potential are advised to use effective contraception during treatment with Duobrii Lotion. It is unknown if Duobrii passes into breast milk.

Tremfya may interact with "live" vaccines and CYP450 substrates. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Tremfya; it is unknown how it would affect a fetus. Human IgG antibodies are known to cross the placental barrier; therefore, Tremfya may be transmitted from the mother to the developing fetus. It is unknown if Tremfya passes into breast milk. Consult your doctor before breastfeeding.

Apply a thin layer dose of Duobrii Lotion to the affected areas once daily.

The dose of Tremfya is 100 mg administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter.